RaySearch Laboratories AB (publ)
STO:RAY B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
RaySearch Laboratories AB (publ)
Cash Equivalents
RaySearch Laboratories AB (publ)
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
RaySearch Laboratories AB (publ)
STO:RAY B
|
Cash Equivalents
kr407.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
ContextVision AB
OSE:CONTX
|
Cash Equivalents
kr69.8m
|
CAGR 3-Years
19%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
M
|
Mentice AB
STO:MNTC
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Ortivus AB
STO:ORTI B
|
Cash Equivalents
kr8.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Sectra AB
STO:SECT B
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
i
|
iZafe Group AB
STO:IZAFE B
|
Cash Equivalents
kr1.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
31%
|
|
RaySearch Laboratories AB (publ)
Glance View
RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. The company is headquartered in Stockholm, Stockholm. The company markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
See Also
What is RaySearch Laboratories AB (publ)'s Cash Equivalents?
Cash Equivalents
407.3m
SEK
Based on the financial report for Dec 31, 2025, RaySearch Laboratories AB (publ)'s Cash Equivalents amounts to 407.3m SEK.
What is RaySearch Laboratories AB (publ)'s Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
19%
Over the last year, the Cash Equivalents growth was -12%. The average annual Cash Equivalents growth rates for RaySearch Laboratories AB (publ) have been 36% over the past three years , 19% over the past five years .
